seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting
February 01 2024 - 4:05PM
seqWell, a global provider of genomic library workflow solutions,
and Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering
company, today announced the creation of an engineered
high-performance transposase enzyme designed to drive superior
performance in sequencing applications. The co-development of this
new transposase enzyme – called TnX transposase – builds upon a
multi-year partnership between the two companies, leveraging
Codexis’ strength in enzyme engineering, and seqWell’s expertise in
developing tools to improve next-generation sequencing (NGS)
performance. Performance data highlighting this enzyme will be
presented during the Advances in Genome Biology and Technology
(AGBT) General Meeting being held February 5 – 8, 2024 in Orlando,
Florida.
“As the NGS technology landscape evolves, the
demand for library prep products that offer enhanced data quality
and high throughput capabilities has never been greater,” said Dan
Calvo, Chief Executive Officer at seqWell. “The TnX transposase
enzyme is an exciting step forward in revolutionizing
high-throughput NGS assays by reducing insertion-site bias and
delivering higher enzyme activity, ultimately enabling our
customers to improve data quality and scale their experiments with
faster and more efficient workflows.”
“Codexis has a long history of leveraging our
proprietary CodeEvolver® technology to develop innovative,
market-leading enzymes, and then working with exceptional partners
to realize each program’s full technical and commercial potential,”
said Stephen Dilly, MBBS, PhD, Chief Executive Officer of Codexis.
“We’re delighted to be working with seqWell on this enhanced
transposase, and look forward to showcasing the data behind our
excitement at AGBT.”
This newly engineered transposase is designed to
exhibit significantly lower bias, potentially providing more
uniform coverage of sequenced DNA; improved activity, converting a
higher percentage of DNA to library; and improved robustness across
a range of assay conditions. seqWell plans to incorporate the TnX
transposase into new NGS workflow kits currently in
development.
“Enzymes play a critical role in sequencing
workflow chemistries,” said Gavin Rush, Vice President of Research
and Development at seqWell. “Engineering better-performing enzymes,
such as TnX transposase, enables the development of higher quality
NGS library preparation products, which will help researchers
generate more accurate, complete, and robust sequencing data.”
Presentation DetailsPoster #505: A Novel Engineered Transposase
(TnX™) for Improved Performance in Genomic ApplicationsLocation:
Palms I BallroomDate: Wednesday, February 7, 2024Time: 4:45 pm –
6:10 pm ET
About seqWell
seqWell creates scalable genomics technologies
that simplify workflows and help enable every life scientist to
unlock transformative discoveries with sequencing. seqWell offers a
range of next-generation library prep products and workflows that
allow customers to achieve higher levels of sample multiplexing
quickly and easily. Learn more about us at www.seqwell.com or
follow us on Linkedin.
About Codexis
Codexis is a leading enzyme engineering company
leveraging its proprietary CodeEvolver® technology platform to
discover, develop and enhance novel, high-performance enzymes and
other classes of proteins. Codexis enzymes solve for real-world
challenges associated with small molecule pharmaceuticals
manufacturing and nucleic acid synthesis. The Company is currently
developing its proprietary ECO Synthesis™ platform to enable the
scaled manufacture of RNAi therapeutics through an enzymatic route.
Codexis’ unique enzymes can drive improvements such as higher
yields, reduced energy usage and waste generation, improved
efficiency in manufacturing and greater sensitivity in genomic and
diagnostic applications. For more information, visit
https://www.codexis.com.
Codexis Forward-Looking
Statements
This press release may contain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. In some cases, you can identify
forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “positioned,” “potential,” “predict,”
“seek,” “should,” “suggest,” “target,” “on track,” “will,” “would”
and other similar expressions that are predictions of or indicate
future events and future trends, or the negative of these terms or
other comparable terminology. To the extent that statements
contained in this press release are not descriptions of historical
facts, they are forward-looking statements reflecting the current
beliefs and expectations of management, including but not limited
to statements regarding the predicted benefits and success of a new
transposase enzyme, the anticipated demand for library prep
products and seqWell’s plans to incorporate such new transposase
into new NGS workflows. You should not place undue reliance on
these forward-looking statements because they involve known and
unknown risks, uncertainties and other factors that are, in some
cases, beyond Codexis’ control and that could materially affect
actual results. Factors that could materially affect actual results
include, among others: Codexis’ dependence on its licensees and
collaborators; if any of its collaborators terminate their
development programs under their respective license agreements with
Codexis; Codexis may need additional capital in the future in order
to expand its business; and if competitors and potential
competitors who have greater resources and experience than Codexis
develop products and technologies that make Codexis’ products and
technologies obsolete. Additional information about factors that
could materially affect actual results can be found in Codexis’
Annual Report on Form 10-K filed with the Securities and Exchange
Commission (“SEC”) on February 27, 2023 and in Codexis’ Quarterly
Report on Form 10-Q filed with the SEC on November 3, 2023,
including under the caption “Risk Factors,” and in Codexis’ other
periodic reports filed with the SEC. Codexis expressly disclaims
any intent or obligation to update these forward-looking
statements, except as required by law.
For More Information
seqWell Contact
Media ContactGwen GordonGwen@gwengordonpr.com
Codexis Contacts
Investor ContactCarrie McKim(336)
608-9706ir@codexis.com
Media ContactLauren Musto(650)
421-8205media@codexis.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024